A Pilot Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Trial Profile

A Pilot Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs 18F-F-AraG (Primary)
  • Indications Head and neck cancer
  • Focus Biomarker; Pharmacodynamics
  • Sponsors CellSight Technologies
  • Most Recent Events

    • 08 May 2017 Status changed from not yet recruiting to recruiting.
    • 01 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.
    • 28 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top